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Psammomys obesusObjective: To examine the effects of rosiglitazone in intramyocellular lipid (IMCL) content in diabetic
Psammomys obesus using novel electron microscopy technologies. Background: P. obesus is an unique
polygenic model of obesity and type 2 diabetes. Male diabetic P. obesus were treated daily with 5 mg/Kg
Rosiglitazone by oral gavage for 14 days. Data were compared with a group of age-matched diabetic P. obesus
treated with saline vehicle. Methods: Assessment of insulin resistance and adiposity were determine before
and after the treatment period by oral glucose tolerance test (oGTT) and dual energy X-ray absorptiometry
(DEXA) analysis. We used a new scanning electron microscopy technology, (WETSEM) to investigate the
effects of rosiglitazone administration on IMCL content, size and distribution in red gastrocnemius muscle.
Results: Rosiglitazone treatment improved glucose tolerance in P. obesus with no difference in the overall
body fat content although a signiﬁcant reduction in subscapular fat mass was observed. Rosiglitazone
changed the distribution of lipid droplet size in skeletal muscle. Treated animals tended to have smaller lipid
droplets compared with saline-treated controls. Conclusions: Since smaller IMCL droplets are associated with
improvements in insulin sensitivity, we propose that this may be an important mechanism by which
rosiglitazone affects glucose tolerance.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Thiazolidinediones (TZD's) such as rosiglitazone improve whole
body insulin sensitivity in both rodents [1,2] and humans with insulin
resistance [3,4]. TZD's act in a range of tissues to improve insulin
sensitivity including adipose tissue [5], skeletal muscle [1,6,7], liver
[1,6] and macrophages [8]. TZD's are also thought to have protective
effects in pancreatic β-cells [9]. The principle mechanism of action of
TZD's is thought to be through agonism of peroxisome proliferator-
activated receptor-gamma (PPARγ), leading to transcriptional regu-
lation of a number of genes in various tissues. Collectively, these
transcriptional changes are thought to cause a re-distribution of lipids
from skeletal muscle and liver to adipose tissue. Together with inc-
reased adipogenesis, this results in increased storage of lipids in
smaller, more insulin sensitive adipocytes, leading to an overall im-
provement in insulin sensitivity [10,11].
Recent studies have demonstrated the importance of inﬂamma-
tion in the development of insulin resistance [12–14]. TZD's have been
shown to have signiﬁcant anti-inﬂammatory effects in a range of in
vitro and in vivo models, and in human subjects [15–18], leading tohool of Exercise and Nutrition
tralia. Tel.: +61 03 5227 2547;
ll rights reserved.some conjecture regarding the principal mechanism of action by
which TZD's improve insulin sensitivity.
Accumulation of triglycerides in skeletal muscle is strongly
associated with insulin resistance, and IMCL content is associated
with both insulin resistance and type 2 diabetes [6,19–23]. However
a paradox has been described whereby highly trained endurance
athletes have high levels of IMCL but are very healthy and highly
insulin sensitive [24–26]. It appears that it is not only the amount of
lipid in skeletal muscle but the size and distribution of the lipid
droplets that determines the level of insulin sensitivity in this
organ.
While it is clear that the accumulation of IMCL is strongly
associated with insulin resistance and the risk of type 2 diabetes,
the effects of rosiglitazone on IMCL levels have been inconsistent.
Several studies have shown that rosiglitazone reduced IMCL in
conjunction with improved insulin sensitivity [27–31], however a
number of other studies have found no change [32] or an increase in
IMCL following treatment with rosiglitazone [33,34].
The aim of the current study was to examine the effects of
rosiglitazone treatment in Psammomys obesus, a polygenic animal
model of obesity and type 2 diabetes. In their natural semi-arid
habitat, these gerbil-like rodents feed on low energy plants such as
saltbush (Atriplex halimus). However, when fed a high caloric diet in
captivity, they develop aspects of the metabolic syndrome charac-
terised by obesity, insulin resistance and hyperglycaemia. [35,36]. To
address the aim of this study we have utilised a novel electron
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IMCL content, size and distribution in skeletal muscle.
2. Materials and methods
2.1. Animals
Male P. obesuswere fed a standard rodent diet (12% of energy from
fat, 63% from carbohydrate and 25% from protein, 3.58 kcal/g;
Barastoc, Pakenham, Australia) after weaning (4 weeks of age) that
induced hyperglycaemia (blood glucoseN8 mmol/L) in ∼15% of the
animals at 16 weeks of age. Animals were housed in a temperature-
controlled room (22±1 °C) with a 12–12 h light-dark cycle. Animals
were maintained in accordance with the Code of Practice of the
National Health and Medical Research Council of Australia, and all
procedures were carried out subject to the approval of the Deakin
University Animal Welfare Committee.
2.2. Study protocol
Two experimental groups (saline or rosiglitazone treated) of 16- to
20-week-old animals were matched for body weight, food consump-
tion and circulating glucose and insulin levels (see Table 1). Both
groups of animals were hyperinsulinemic but normoglycaemic at the
beginning of the study. Each group was treated by daily oral gavage of
rosiglitazone (5 mg/kg) or saline (control) for 14 days. Body weight
and food intake were measured weekly. Blood samples were collected
for assessment of circulating glucose and insulin levels on days 0, 7
and 14. At the start and end of the study, all animals had energy
homoeostasis assessed by indirect calorimetry (24 h), and body
composition measured by DEXA analysis. An oral glucose tolerance
test (2 g/kg glucose) was performed on day 14.
2.3. WETSEM technology: background
Red gastrocnemius muscle was harvested and immersed in
formalin, and longitudinally cut to a thickness of 0.5–1 mm, and
stained with phosphtungstic acid (PTA; Sigma, St. Louis, MO), which
highlights proteins and membranous structures. Using this staining
methodology, intracellular features were highlighted brightly where-
as lipid droplets remained unstained in black.
The WETSEM technology is especially useful to resolve lipid
compartments in the cell, based on their rich carbon content
compared with other cellular structures richer in oxygen atoms. The
WETSEM technique was described recently in detail [37–39]. Brieﬂy,
each stained muscle section was absorbed onto a thin partition
membrane transparent to electrons inside a sample capsule (Quanto-
miX Ltd. Nes Ziona, Israel) and placed on the specimen stage of the
SEM under vacuum. Images were obtained on an FEI XL-30
(Eindhoven, The Netherlands) scanning electron microscope (elec-
tron beam energy of 15–30 kV, beam current of 200–800 pA, with scan
rates of 1.3–120 ms/line at 484 lines/frame).Table 1
Characteristics of saline and rosiglitazone treated P. obesus.
Saline 5 mg/kg Rosiglitazone
Day 0 Day 14 Day 0 Day 14
Body weight (g) 228.5±6.4 225.3±8.0 228.3±5.6 223.8±5.3
Fat mass (% body weight
by DEXA)
19.1±1.2 17.6±1.3 17.4±1.6 16.3±1.4
Fasting blood glucose
(mM)
6.0±0.6 5.4±0.7 6.2±0.8 5.0±0.6*
Fasting plasma insulin
(μU/ml)
659±136 438±91 410±69 245±53
Data are expressed as mean ± SEM (n=20-19). *p = 0.006 vs corresponding day 0.2.4. Assessment of lipid accumulation in muscle
For each animal, a total of 40 ﬁbers were imaged, representing
different longitudinal muscle ﬁbers per sample. Determination of
IMCL droplet size and total amount was performed using custom-
made in-house software (QuantomiX, Nes Ziona, Israel). Typical reso-
lution of choice for image processing was as shown in Fig. 3.
2.5. Statistical analysis
The relationship between the dependent variable from the IMCL
data, and several independent variables from the blood bioche-
mical data was analyzed by multiple regression analysis using SAS
software.
3. Results
3.1. Effects of rosiglitazone in Psammomys obesus
Treatment with rosiglitazone had no effect on body weight,
percentage body fat (assessed by DEXA) or plasma insulin concen-
tration in P. obesus (Table 1). However, rosiglitazone treatment
caused a signiﬁcant reduction in mean blood glucose concentration
(p=0.006), and was associated with improved glucose tolerance as
measured by OGTT (Fig. 1). During the OGTT, blood glucose
concentrations were signiﬁcantly lower in rosiglitazone treated P.
obesus compared with controls after 45 min (p=0.04), 60 min
(p=0.04) and 90 min (p=0.01), consistent with an improvement in
glucose tolerance following treatment with rosiglitazone. Further-
more, after 14 days of rosiglitazone treatment (5 mg/kg/day), the
area under the glucose curve in an OGTT was reduced by 19%
(p=0.039) compared with controls (Fig. 1b).
There was no difference in the weights of major organs (liver,
heart, pancreas, spleen, heart, adrenal gland, and testis) in the
rosiglitazone treated animals compared with saline treated controls.Fig. 1. (a) OGTT blood glucose data showing that rosiglitazone improves glucose
tolerance in P. obesus. ⁎pb0.05 compared with saline treated control animals. (b) Area
under the blood glucose curve (OGTT) data showing an improvement in glucose
tolerance following rosiglitazone treatment in P. obesus. ⁎p=0.039.
Fig. 2. Fat pad weights from P. obesus treated with rosiglitazone or saline (control).
⁎p=0.025.
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the combined weight of the various adipose tissue depots was not
different between the groups (rosiglitazone 12.0±1.2 vs. saline
14.7±1.7 g, p=0.20). In the animals treated with rosiglitazone, the
weight of the sub-scapular (subcutaneous) fat pad was reduced by
38% when compared with the saline treated control animals (Fig. 2,
p=0.025). This difference remained when the sub-scapular fat pad
mass was expressed as a percentage of body weight (rosiglitazone
1.24±0.11 vs. saline 1.92±0.27 % of body weight, p=0.020).
There was no signiﬁcant difference in the mass (or percentage of
body weight) for any of the other adipose depots tested (peri-renal,
epididymal, mesenteric or intramuscular; Fig. 2), nor for any of the
skeletal muscles measured (data not shown).Fig. 3. Wet SEM images of skeletal muscle from P. obesus treated with rosiglitazone (c and
image.Treatment of P. obesus with rosiglitazone had no effect on total
energy expenditure, physical activity, or whole-body fat or carbohy-
drate oxidation as measured by indirect calorimetry in P. obesus.
3.2. Imaging and quantitative analysis of IMCL
Fig. 3 shows a series of representative muscle images taken at
different magniﬁcations, using the WETSEM technique. The high-
resolution images of the muscle ﬁbers, showing the precise structure
of the striated skeletal muscle, the IMCL droplets and the mitochon-
dria, enabled determination of IMCL droplet size.
Total IMCL content per ﬁbre area was not signiﬁcantly different
between the treatment groups, although IMCL tended to be lower in
the rosiglitazone treated animals (Fig. 4a). Analysis of IMCL droplet
size distribution indicated a pattern of reduced lipid droplet size in the
skeletal muscle of P. obesus treated with rosiglitazone (shown in black
bars) compared with control animals (white bars; Fig. 4b). There was
signiﬁcantly reduced incidence of larger lipid droplets in the rosi-
glitazone treated animals, relative to the controls (χ2=9.9, pb0.05).
3.3. Correlation between physiological parameters and IMCL analysis
We used multiple regression analysis to investigate relationships
between physiological data and the IMCL data set obtained from the
WETSEM technique. When all animals were analyzed together, a
combination of the area under the curve of the OGTT results (OGTT-
AUC) and the percentage body fat at day 14 was signiﬁcantly
associated with IMCL droplet size (R2=0.44). Within the saline
treated animals, OGTT-AUC (p=0.02) and fat content at day 14
(p=0.009) were strongly and independently associated with IMCL
droplet size (R2=0.74).d) or saline (controls; a and b). Scale bars are shown in the lower right corner of each
Fig. 4. (a) Total IMCL per ﬁbre area in P. obesus treated with rosiglitazone and saline. (b)
IMCL droplet size distribution (normalised to the mean per 10 ﬁbres) in rosiglitazone
(black bars) and saline (control; white bars) treated P. obesus. χ2=9.9, pb0.05.
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In this study we have shown that treatment with rosiglitazone
(5 mg/kg) for 14 days signiﬁcantly improved glucose tolerance in P.
obesus. The improvement in glucose tolerance was not associated
with a change in total IMCL, but there was a trend for a reduction in
lipid droplet size in skeletal muscle following rosiglitazone treatment.
Furthermore, we demonstrated that IMCL was signiﬁcantly associated
with glucose tolerance and overall body fat content. Collectively, these
data suggest that the effect of rosiglitazone on glucose tolerance may
be mediated in part by changing the distribution of lipid droplet size
in skeletal muscle, even if there is no overall reduction in total IMCL.
Treatment with rosiglitazone did not affect body weight or body
fat content in P. obesus. However, the mass of the sub-scapular fat
pad was reduced in the treated animals compared with controls.
There was no difference between the groups for any of the other fat
pads measured, and the relevance of this ﬁnding to the overall effects
of rosiglitazone on glucose tolerance is unknown. However, this
ﬁnding does provide additional evidence to the suggestion that treat-
ment with rosiglitazone results in re-distribution of lipids between
tissues.
The relationship between IMCL and insulin resistance is well
established [19–23]. However, the effects of rosiglitazone on IMCL are
less clear [32–34], and there is some conjecture regarding the
mechanisms by which this drug improves insulin sensitivity. Here
we provide evidence to suggest that rosiglitazone treatment results in
a reduction in lipid droplet size in skeletal muscle without a
signiﬁcant change in total IMCL. Hefetz and colleagues [40] also
reported no change in the total lipid content in skeletal muscle from
diabetic P. obesus following rosiglitazone treatment, although they
did not examine the size distribution of the lipid droplets. Interest-
ingly, microscopy analysis of pancreatic sections revealed that
rosiglitazone prevented the decrease in insulin immunostaining
induced by the high energy diet and accelerated β-cell proliferation
(measured by BrdU incorporation into nuclei) [40]. Based on theseobservations, Hefetz et al. concluded that the major anti-diabetic
action of rosiglitazone in P. obesuswas by preventing the deterioration
of pancreatic function. While we have not formally examined insulin
content in β-cell islets in this study, we observed no change in
circulating insulin levels after rosiglitazone treatment. This suggests
that the beneﬁcial effects of rosiglitazone on glycaemia and glucose
tolerance shown in this study are not likely due to an increase in
insulin secretion. The alternative conclusions reached in both studies
may be due to differences in the dose of rosiglitazone and the high
calorie feeding protocol used.
We believe that a reduction in lipid droplet size in skeletal muscle
may be an important factor in the improvement in glucose tolerance
observed in these animals Consistent with this hypothesis, Fraenkel et
al. [41] showed that a decrease in the number of large lipid droplets in
skeletal muscle was associated with reduced hyperglycaemia when
high energy diet induced-diabetic P. obesus were switched to a low
energy diet. Likewise, He and colleagues [42] showed a profound
increase in insulin sensitivity following exercise training and weight
loss in obese subjects, with no change in total IMCL. However the size
of intramuscular lipid droplets was signiﬁcantly reduced and this
reduction was correlated with insulin sensitivity [42]. One potential
mechanism by which a reduction in lipid droplet size may be
associated with insulin sensitivity independent of total IMCL is
through an increased surface to volume ratio of the droplets, which
increases the proportion of PAT proteins (perilipin, adipophilin, and
TIP47) relative to triglyceride content, in turn improving the access of
cytosolic lipases to the lipids [43]. It has also been suggested that
smaller lipid droplets are more accessible to oxidation by mitochon-
dria [42].
The improvement in glucose tolerance with reductions in lipid
droplet size but no change in total IMCL is also consistent with the
“athletes paradox”. Highly trained endurance athletes have high
levels of IMCL but are highly insulin sensitive [24–26].
These observations have been explained by the fact that oxidative
capacity is greatly increased following exercise training, although the
precise role of lipid droplet size and subcellular location have not been
fully explored. Our results, alongwith those of others [42] suggest that
lipid droplet size may be an important determinant of insulin
sensitivity of skeletal muscle, and that this is one mechanism by
which rosiglitazone can affect glucose tolerance.
In summary, rosiglitazone improved glucose tolerance in P. obesus,
and this effect was associated with a re-distribution of lipid droplet
size in skeletal muscle. We hypothesise that this may be an important
aspect of the mechanism of action of rosiglitazone, and could explain
some of the inconsistent results seen previously regarding the effects
of rosiglitazone on IMCL. Future studies should include assessment of
not only of total IMCL, but also of the size of the lipid droplets in
skeletal muscle.
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